173 results about "Nasopharynx carcinoma" patented technology

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The application relates to a culture medium for nasopharyngeal carcinoma organs, and methods for culturing and identifying the nasopharyngeal carcinoma organs. According to the culture and growth characteristics of nasopharyngeal carcinoma-derived cells, a variety of cytokine components are selected and blended according to a certain ratio; the contents of cytokines and signal pathway regulatory factors in the culture medium are suitable; the nasopharyngeal carcinoma cells can effectively form organoids in a three-dimensional (3D) environment. The methods for culturing and identifying the nasopharyngeal carcinoma organs as well as the unique culture medium for the nasopharyngeal carcinoma organs can be used for successfully and stably culturing the nasopharyngeal carcinoma organs which have pathophysiological features and genotypes being highly consistent with those of the parental tumor and have high similar form of organization.

The invention discloses a nasopharyngeal carcinoma structured image report and data processing system and a nasopharyngeal carcinoma structured image report and data processing method. The system comprises a clinical data collection module, a fine image analysis and report module, a comprehensive processing module and a clinical decision module, is mainly used for inputting and analyzing nasopharyngeal carcinoma imaging diagnosis report data and comprehensively and systematically recording the nasopharyngeal carcinoma invasion surrounding anatomical structure and lymph node metastasis conditions in a structural data form, and establishes a nasopharyngeal carcinoma structural image report standard for constructing a nasopharyngeal carcinoma image big database and a nasopharyngeal carcinomaartificial intelligence prediction model. According to the system, an MR fine film reading database is established to standardize a nasopharyngeal carcinoma image report, and a set of a nasopharyngealcarcinoma online clinical decision platform is developed on the basis to further assist nasopharyngeal carcinoma staging and typing, treatment scheme recommendation and prognosis prediction, so thatclinicians are helped to well formulate a treatment scheme according to an MRI image evaluation result.

The invention relates to an N'-5-substitutent aryl-2-furan-N-substitutent benzoyl hydyne compound (I) with a novel structure. The compound is produced by reaction of substituted aryl formohydrazide and 5-substitent aryl furan-2-formaldehyde. The compound is found through research to have anti-tumor activities in which people are interested, particularly the activities for resisting stomach cancer, human liver cancer and nasopharynx cancer.

The invention relates to a kit used for detecting nasopharyngeal carcinoma and an application thereof. The kit includes a sample DNA extraction reagent, a DNA methylation modification conversion reagent, and a reagent for detecting methylation of MSF1 gene and RASSF1A gene based on a fluorescent quantitative PCR method. Methylation PCR-amplified primer sequences of the MSF1 gene and the RASSF1A gene contain a CpG sequence. The kit simultaneously uses the MSF1 and RASSF1A genes for detecting of nasopharyngeal carcinoma, and the sensitivity and specificity are significantly improved compared with the sensitivity and specificity of the detection by the single use of the MSF1 gene or the RASSF1A gene.

The invention discloses a pharmaceutical composition for treating acute or chronic myeloblastic leukemia, which is characterized in that: it is made of dehydrated galactitol, kudzuvine root and pharmaceutical auxiliary materials. The composition in the invention has evident effect for treating leukemia, has an undoubted effect for treating lung cancer, multiple myeloma and nasopharyngeal carcinoma, especially has a preferable near term effect for treating chronic myeloblastic leukemia with a remission rate of 86%, has a higher effect for treating various lung cancer, and has lower poisonous and side effects.

The invention relates to an endoscopic ultrasonic imaging device and an endoscopic ultrasonic imaging method for nasopharynx cancer. The device comprises a camera, a video signal processing unit, a control and imaging unit, an ultrasonic excitation and receiving unit and an ultrasonic transducer, wherein the camera is used for acquiring an optical tissue image on the inner surface of a nasopharynx; the video signal processing unit is used for converting an optical tissue image signal into a video digital signal; the control and imaging unit is used for storing and displaying the digital signal and sending a control instruction; the ultrasonic excitation and receiving unit is used for generating a specific pulse signal according to an ultrasonic control instruction for ultrasonic excitation, processing an ultrasonic echo signal and then performing ultrasonic image display; the ultrasonic transducer is used for generating an ultrasonic wave for scanning the interior of the nasopharynx according to the pulse signal, receiving the ultrasonic echo signal and converting the ultrasonic echo signal into an electric echo signal; the ultrasonic excitation and receiving unit is also used for processing the electric echo signal; the control and imaging unit is also used for performing ultrasonic imaging according to the processed electric echo signal. The detection accuracy is improved.

The present invention discloses an Indian strawberry phenol extraction extracted from an Indian strawberry whole grass, which also relates to the preparation method of the extraction and the function of the extraction. The preparation method of the Indian strawberry phenol extraction is as following, which comprises soaking and extraction of the Indian strawberry by water, ethanol, or a mixed solution with water and ethanol in a certain ratio; vacuum concentration of the Indian strawberry extraction liquid; then the ethanol is removed from the extraction liquid and passed through a malodorous resin column; the liquid is eluted by the ethanol after elution of the non affection component with the water; the ethanol elution liquid and vacuum concentration are collected, therefore the Indian strawberry phenol extraction is obtained. The Indian strawberry phenol extraction of the present invention possesses functions of prohibiting the generation and growth of various kinds of tumor cells. Therefore the present invention is applicable for treatment of a plurality of cancer diseases comprising the lung cancer, the liver cancer, the nasopharynx cancer, the gastric cancer, the cervical cancer, the endometrium cancer and the ovarian cancer, etc. In addition, the Indian strawberry phenol extraction in the present invention has active function of improving the immune ability in the organism.

The invention discloses a glaucocalyxin B derivative, a preparation method and application thereof. The glaucocalyxin B (GLB) is used as a main body of the glaucocalyxin B (GLB) derivative which is a diterpenes substance and has an ent-kaurane structure, carbonyl, polypeptide cNGQGEQc and / or hydroxyl. In the invention, rabdosia amethystoides medicinal material (part on the above-ground) is used as a raw material, and the preparation method of the derivative is as follows: crashing the raw material, extracting, treating solution, passing through a column, recrystallizing and carrying out other steps to obtain the glaucocalyxin B (GLB), and further carrying out acetylation on the glaucocalyxin B (GLB) and the polypeptide cNGQGEQc to obtain the glaucocalyxin B (GLB) derivative. The glaucocalyxin B (GLB) derivative has high anticancer activity, can significantly inhibit a plurality of tumor cells such as cells in lung cancer, liver cancer, nasopharyngeal carcinoma, lymphoma, melanoma and myelomatosis, especially has a targeting effect on the lung caner and can pertinently treat the lung caner.

The invention discloses a nasopharyngeal carcinoma EB virus serum antibody tag detection chip and a kit thereof. Nasopharyngeal carcinoma can be detected effectively by detecting the expression of EBV serum antibody BMRF1-IgG, LF1-IgA, BNLF2b-IgA, BKRF4-IgG, BMRF1-IgA, BXLF1-IgG, BaRF1-IgG, BKRF3-IgG, BZLF1-E1-IgG and BNLF2b-IgG. The nasopharyngeal carcinoma detection chip and kit provided by the invention have very good specificity and high sensitivity, and can be effectively used for nasopharynx screening, early clinical diagnosis and prognosis evaluation, etc.

The invention provides an EBV capture probe and a method for acquiring EBV genome sequence information in a sample. The capture probe designed by the invention has the following advantages: the capture efficiency on various EBV infection-associated diseases such as lymphoma, nasopharynx cancer and gastric cancer as well as EBV-containing cell lines (C666, Raji and snu179) is relatively high, the coverage degree is close to 100 percent and the sequencing data coverage is uniform, so that the chip can capture the information of the EVB genome well and has important significance in deep researchon the virus.

The invention provides a drug loading system of a tetrahedral structure. The structure of the drug loading system is Aptamer-AS1411-DNA. The structure of the drug loading system is Aptamer1-AS1411-DNA, and particularly the structure is formed by simultaneously connecting one Aptamer1 and three AS1411 onto a DNA tetrahedral body in an alkali complementary pairing way. The drug loading system is applied to a nasopharynx cancer drug, and is particularly applied to a drug targeting CD44<+> nasopharynx cancer cells; and meanwhile, the drug loading system is applied to a drug inhibiting the multiplication of nasopharynx cancer 5-8F cells.

The invention provides a preparation method of a probiotics micro-ecological medicine assisting in treatment of nasopharynx cancer. According to the technical scheme, probiotics are separated from theintestines of healthy people from a cancer-free village in Wuyuan; after identification, the acid resistance, the cholate resistance, the oxidation resistance and the antibacterial property of the probiotics are evaluated; strains with good adhesive ability to nasopharynx cancer cells are screened out by combining co-culture and microscopic examination observation. Based on this, the screened strains are compounded with conventional probiotics such as animal bifidobacteria, lactobacillus rhamnosus and lactobacillus acidophilus, and the content proportion and the viable bacteria concentrationare limited. According to the preparation method provided by the invention, the screened strains all come from the human intestines s, the bifidobacteria and the lactic acid bacteria are taken as mainaddition objects for compounding; theoretically, the strains are safe to human body and do not cause any toxic or side effect; according to the method, at least one strain of bifidobacteria with an exact curative effect on nasopharynx cancer patients is added, and the effectiveness of nasopharynx cancertreatment is ensured; the adopted probiotics are directly screened from the healthy people in the cancer-free village, and thus the medicine has the advantage of low price over other medicines.

The invention discloses an application of miR-17, miR-20a, miR-29c and miR-223 as nasopharyngeal carcinoma molecular markers. The invention provides the 4 micro-RNAs in serum and as the nasopharyngeal carcinoma molecular markers and a detection method thereof, wherein the detection method comprises the steps: total RNAs in peripheral blood serum are extracted and subjected to reverse transcription into cDNAs, Ct values of the 4 micro-RNAs are obtained through a real-time quantitative PCR method, and the A value is calculated through a formula of A=(Ct[miR-29c]+Ct[miR-223])-(Ct[miR-17]+Ct[miR-20a]); if the A value is greater than -3.30, the result is positive, and a patient is prompted to be suffered from nasopharyngeal carcinoma; and if the A value is less than -3.30, the result is negative, and the patient is prompted to be not suffered from nasopharyngeal carcinoma. Through detection of expression conditions of the 4 micro-RNAs in the peripheral blood of various crowds, the risk of attacking nasopharyngeal carcinoma is predicted, the detection method is used for screening crowds with high risk of nasopharyngeal carcinoma, and the rapid and noninvasive diagnosis on nasopharyngeal carcinoma patients is achieved.

The invention discloses an application of EB virus encoded microRNA BART10 (EBV-miR-BART10) in preparing a prediction preparation for recurrence and metastasis of nasopharyngeal carcinoma. The research proves that the expression level of EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is in positive correlation with the lymphatic metastasis and the distant metastasis of the nasopharyngeal carcinoma patient; if the expression of the EBV-miR-BART10 in the nasopharyngeal carcinoma tissue is up-regulated, the nasopharyngeal carcinoma patient with higher EBV-miR-BART10 expression have larger possibilities of recurrence and metastasis than the nasopharyngeal carcinoma patient with lower EBV-miR-BART10 expression, and the prognosis is worse, therefore, the application of the expression of the EBV-miR-BART10 in the predication of recurrence and metastasis of the nasopharyngeal carcinoma patient can provide powerful biomolecular basis for the prognosis of the nasopharyngeal carcinoma patient, and thus the application method has profound clinical significances and important popularization and application prospects.

The invention relates to a quantitative fluorescent multiplex PCR test kit for Epstein-Barr virus, and the kit comprises the following reagents: a, specific primer pairs for amplifying mutations of key target genes in the Epstein-Barr virus; and b, specific probes for the mutations of key target genes in the Epstein-Barr virus, wherein the mutations are P-thr, V-val and V-leu in the coding region of EBNA-1 gene, promoters Cp, Fp and Zp of the EBNA-1 gene, and XhoI-loss, 30bp Deletion and Ser 366 Thr of LMP1 gene. The test kit is advantageous in that: the aim of precise prediction of the risk of nasopharyngeal carcinoma in high risk population can be achieved; the main carcinogenic mutations can be well known for the combination of population screening and population intervention for nasopharyngeal carcinoma; and the kit has the advantages of high in sensitivity, fast in test, and low in cost, having broad market prospect.

The invention discloses an early nasopharyngeal carcinoma serum specific protein and application thereof, belonging to the field of biological detection technique. The invention uses an SELDI-TOF-MS technique, establishes the fingerprint of serum protein between the nasopharyngeal carcinoma patient and healthy contrasting person, carries out the variation analysis and searches new protein markers, thus carrying out early checking and detection on the nasopharyngeal carcinoma. As the SELDI-TOF-MS technique is applied to the invention, mass spectrometric detection and analysis are carried out on the serum of the peripheral blood of nasopharyngeal carcinoma patients from the point of view of proteomics, thus establishing effective nasopharyngeal carcinoma serum protein fingerprint which is used for the risk evaluation method used when the nasopharyngeal carcinoma is detected outside the body. The method can be used as the auxiliary checking mean of nasopharyngeal carcinoma non-invasion.

The invention discloses a culture medium special for organoids of nasopharyngeal carcinoma and a scaffold-free culture method. The culture medium comprises EGF, Noggin, Y-27632, A83-01, SB202190, bFGF, hydrocortisone, Insulin, penicillin-streptomycin, FBS and Keratinocyte-SFM. The culture method comprises the following steps: inoculating separated tumor cells of nasopharyngeal carcinoma into an ultra-low adsorption U-shaped cell culture plate, adding the culture medium special for organoids of nasopharyngeal carcinoma, performing centrifugation, performing culture in a CO2 incubator with a volume concentration of 5% at a temperature of 37 DEG C, and replacing a scaffold-free culture medium once every 3-4 days. According to the culture medium special for organoids of nasopharyngeal carcinoma and the scaffold-free culture method, introduction of an exogenous scaffold material is not needed, cell aggregation and clustering can be promoted under the assistance of gravity, rapid amplification of the tumor cells in a short time is achieved so as to construct the organoids, the success rate can reach 100%, and the specificity of primary tumor can be maintained; and meanwhile, the activityand functional and high expression of the tumor cells can be maintained for a long period of time.

The invention provides a group of markers for predicting the metastasis risk of nasopharyngeal carcinoma. The markers comprise PDL1, CD163, CXCR5 and CD117. The molecular label formed by expression ofthe four immune molecules can reflect the biological specificity of a nasopharyngeal carcinoma patient, can more accurately predict the metastasis risk and prognosis of the nasopharyngeal carcinoma patient and better guide clinical medication, and the prediction efficiency of the molecular label for non-distant survival is superior to that of traditional N stages.

The invention discloses an N-(4-(4-(pyridine-2-radical) piperazine-1-radical) pyrimidine-2-radical) amide of a structural formula (I). When X2 is -CH3, X1 is taken from one of -H, -CH3 or -Br arbitrarily; when X2 is -H, X1 is taken from one of -H, -Br and -CI arbitrarily; X3 is taken from -H or one of -H arbitrarily; and X4 is taken from -H. Organic salt or inorganic salt such as hydrochloride, sulfate, phosphate, mesylate, sulfonate, formate, acetate, malate or lactate acceptable in pharmacy is provided. The invention further relates to a preparation method of the compound and application of the compound and the salt acceptable in the pharmacy in preparation of antineoplastic drugs and particularly in preparation of drugs for treating lung cancer, liver cancer, gastric cancer and nasopharynx cancer.

The present invention belongs to the technical field of medicines and specifically relates to an application of ulinastatin in preparations of anti-nasopharyngeal carcinoma metastasis medicines. Through cell in-vitro tests, the ulinastatin is found to be capable of inhibiting metastasis of nasopharyngeal carcinoma cells, does not inhibit growth of the nasopharyngeal carcinoma cells, and is less toxic and more conducive to rehabilitation of patients with nasopharyngeal carcinoma.

The invention belongs to the field of medicines and particularly relates to an application of physcion and a derivative thereof in preparation of antitumor drugs. The activity of a liver cancer cell, a lung cancer cell, a breast cancer cell, a colon cancer cell, a nasopharynx cancer cell, a gastric cancer cell, a human oral epidermoid carcinoma cell and a chronic myelogenous leukemia cell can be effectively inhibited by employing a pharmaceutical composition containing the physcion and the derivative thereof as active components, and especially the pharmaceutical composition has a more significant inhibition effect on the liver cancer cell, the lung cancer cell and the colon cancer cell. The physcion and the derivative thereof have an anti-tumor effect of inhibiting transplantation tumor growth for tumor-bearing nude mice with a liver cancer, a lung cancer and a colon cancer. Furthermore, the physcion and the derivative thereof have no toxic and side effect on a normal body. A foundation is laid for development of high-efficiency and low-toxicity novel broad-spectrum anti-tumor drugs of the physcion and the derivative thereof.

Through a genetic engineering technology, a LMP2A-targeted chimeric antigen receptor extracellular region LMP2A scFv segment is constructed by using a high affinity full human anti-LMP2A Fab as a template. A third generation LMP2A-targeted chimeric antigen receptor is constructed by recombination of the LMP2A-targeted chimeric antigen receptor(LMP2A CAR) extracellular region LMP2A scFv segment andsignal peptide CD8alpha, transmembrane region CD8TM and intracellular regions CD28, CD137 and CD3 zeta. The prepared LMP2A-targeted chimeric antigen receptor is recombined into a linearized lentiviral vector by overlay PCR to construct an anti-LMP2A CAR lentiviral expression vector, a LMP2A CAR virus solution is prepared, and T cells are infected to obtain LMP2A CAR-T cells. In vitro and in vivotests validate the LMP2A CAR-T cells have specific targeted killing effects on LMP2A positive nasopharyngeal carcinoma cells, and provide a new therapeutic idea and means for the treatment of nasopharyngeal carcinoma.

The invention relates to the field of biology, and discloses a double-gene co-expression recombinant plasmid pAdTrack-CMV-IL-24-polyA-promoter-OSM with the preservation number as China center for type culture connection number (CCTTCC NO.): M2011378, and a recombinant adenovirus Ad-IL-24-polyA-promoter-OSM prepared by the plasmid. An IL-24 gene and an OSM gene are subcloned between Ad-polyA-promoter empty carriers to construct the IL-24 and OSM double-gene co-expression recombinant plasmid, homologous recombination is performed between the recombinant plasmid and an adenovirus pAdEasy-1 to generate the recombinant adenovirus in packaging mode in a QBI-293A cell. The recombinant adenovirus has synergistic effect on inhibition of melanoma and cancer cells of nasopharyngeal darcinoma, and simultaneously has synergistic effect on radiosensitivity of the cancer cells of the nasopharyngeal darcinoma.

The invention discloses application of EB virus encoded microRNA BART6-3p to preparation of a nasopharyngeal cancer prognostic preparation. EB virus encoded microRNA BART6-3p is mainly used for preparing preparations for monitoring recurrence and metastasis and forecasting prognosis of nasopharyngeal cancer. Close relation between expression of BART 6-3p and prognosis of a nasopharyngeal cancer patient is discovered in a filed nasopharyngeal cancer paraffin-embedded tissue sample through in-situ hybridization, negative correlation between the expression level of BART6-3p and metastasis of the nasopharyngeal cancer patient is detected in nasopharyngeal cancer tissues, the lifetime of the patient with high expression of BART6-3p is longer, and the BART6-3p can serve as a predictive molecular marker of recurrence and metastasis of nasopharyngeal cancer. The application provided by the invention provides a powerful molecular biology tool for auxiliary diagnosis and prognosis forecasting of nasopharyngeal cancer and has profound clinical significance and important popularization and application prospects.

The invention relates to an EBV virus LMP1 targeted oligonucleotide and also relates to application of the oligonucleotide in treatment and radiotherapeutic sensitization of nasopharyngeal darcinoma. The oligonucleotide has the following characteristics that: (1) the oligonucleotide is complementary with an EBV LMP1 gene through the oligonucleotide binding sequence; (2) the oligonucleotide consists of 11-70 ribonucleotides, and the ribonucleotides are connected by organic phosphate bonds from the 5' direction to the 3' direction; (3) the 2' site of ribose has a methoxy-substituted radical; and (4) the 3' end is connected with a butanol radical. The modified oligonucleotides have relatively high enzymolysis resistance and biological activity, and can serve as an effective medicine for treating or assisting to treat nasopharyngeal darcinoma or EBV relevant diseases.

The invention discloses application of indeno triazine compounds as a substrate of quinone oxidoreductase depending on NAD (P) H. The indeno triazine compounds are catalyzed through the quinone oxidoreductase depending on the NAD (P) H to generate an oxidation reduction cycle reaction, a large number of reactive oxide free radicals are generated, strong oxidative stress is induced, and the obvious lethal effect on lung cancer, liver cancer, cervical cancer, pancreatic cancer, breast cancer, prostate cancer, nasopharynx cancer, kidney clear cell carcinoma, oral epidermoid carcinoma, chronic myelogenous leukemia, intestinal cancer, brain cancer, gastric cancer, esophagus cancer and other cancer cells expressed by the quinone oxidoreductase depending on the NAD (P) H is achieved. The indeno triazine compounds used as the substrate of the quinone oxidoreductase depending on the NAD (P) H can also be used as sensitizers for treating the cancer with radiotherapy, and have the obvious anticancer synergistic effect. In addition, the indeno triazine compounds used as the substrate of the quinone oxidoreductase depending on the NAD (P) H have antibacterial and antifungal activity.

The invention relates to the field of medicines, and specifically discloses a pharmaceutical composition with anticancer effect. The pharmaceutical composition comprises the following active ingredients: resibufogenin, cinobufagin and bufotalin; wherein the weight ratio of resibufogenin, cinobufagin and bufotalin is 1-2:1-5:1-3. Tests show that after combination of the resibufogenin, the cinobufagin and the bufotalin, a synergistic anti liver cancer, lung cancer and nasopharyngeal carcinoma effect can be played, when the weight ratio of resibufogenin, cinobufagin and bufotalin is 1:1.5-2.5:1-2, the synergistic anti liver cancer effect is best, the anti liver and lung cancer effect of the pharmaceutical composition is equivalent to that of positive control drug cisplatin, and the anti nasopharyngeal carcinoma effect of the pharmaceutical composition better than that of the positive control drug cisplatin, so that the resibufogenin, the cinobufagin and the bufotalin can be combinedly used as a new anticancer drug.

The invention discloses a mouth opening training device for nasopharynx cancer. The mouth opening training device is composed of a trainer held in the mouth and a fixing device, wherein the trainer held in the mouth is fixedly arranged on the fixing device. When the mouth opening training device is used, a patient holds the trainer in the mouth, a fixing belt is fixed to the head of the patient, according to the conditions of the patient, a handle is rotated, a rotation rod rotates, a first tooth occluding block and a second tooth occluding block move vertically for controlling the mouth opening size of the patient, then the mouth opening training is carried out on the patient, after the mouth opening training of the patient is finished, the device is taken down, and a first silicon rubber case and a second silicon rubber case can be replaced, so that the operation is clean and sanitary. The mouth opening training device is simple in structure and convenient to operate, and is safe and comfortable, the replacement is convenient and sanitary during use each time, the patient is passively treated and complies with the treatment for a long term, the complications of the patient are effectively reduced, the mouth opening size can be finely adjusted, the mouth opening training device is applicable to patients in different disease conditions, the training purpose is achieved, the patients can carry out operation independently, the treatment effects are improved, the device has great significant for preventing the generation of mouth opening difficulty of the patients, and the cost is low.